Ghrelin-receptor research
Ipamorelin Research review
A human trial exists, but its surgical setting and negative efficacy result matter when assessing wellness claims.
01 / Context first
The research setting
Hospital patients recovering from bowel surgery received intravenous ipamorelin or placebo.
02 / The findings
What the sources found
- The selected trial found no statistically significant improvement in its key or secondary efficacy analyses.
03 / The open questions
Where the evidence stops
- This was a small postoperative study, not a test of muscle gain, sleep, or anti-aging.
- Its findings do not establish benefits or safety for other routes or prolonged use.
04 / Safety context
Before drawing conclusions
FDA flags immune-response concerns and serious adverse events reported during intravenous use; other injection routes lack adequate safety information.
These reviews do not provide instructions for self-treatment. Discuss personal medical questions with a qualified clinician.
05 / Go to the originals
Read the sources
Inspect the original research and regulatory context behind this review.
- Original research — PubMed abstractProspective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. ↗
- FDA safety informationCertain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks ↗
Sources checked September 12, 2026. Next editorial review due December 11, 2026.
Read the review methodology →